• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Cardiology

Non-vitamin K oral anticoagulants associated with superior stroke prevention over warfarin among patients with nonvalvular atrial fibrillation

byJake EngelandMichael Pratte
August 16, 2021
in Cardiology, Emergency, Hematology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Non-vitamin K antagonist oral anticoagulants (NOACs) were associated with decreased stroke/ systemic embolism risk compared to warfarin among patients with nonvalvular atrial fibrillation at high risk for bleeding.

2. In comparison to warfarin, apixaban and dabigatran were associated with reduced risk of major bleeding; however, rivaroxaban was associated with increased risk for a major bleeding event.

Evidence Rating Level: 2 (Good)

Study Rundown: Management of atrial fibrillation (AF) involves oral anticoagulation to reduce stroke risk. Various oral anticoagulants (OACs) are used, including vitamin K antagonists and non-vitamin K antagonists, to prevent stroke without leaving the patient at high risk for major bleeding (MB). This secondary analysis of the ARISTOPHANES study investigated rates of stroke/systemic embolism (SE) and MB among patients with nonvalvular AF and a high risk of gastrointestinal (GI) bleeding; they were prescribed warfarin or a non-vitamin K antagonist OAC (NOAC) (apixaban, dabigatran, or rivaroxaban). All three NOACs demonstrated a lower risk of stroke/SE than warfarin. When assessing MB rates, those prescribed apixaban and dabigatran had reduced risk, whereas patients on rivaroxaban had a higher risk compared to warfarin. When comparing the NOACs to each other, those taking apixaban had a lower risk of stroke and a lower risk of MB compared to dabigatran and rivaroxaban. Overall, NOACs were superior to warfarin in reducing stroke risk; however, the risk of MB differed between NOACs. This was the largest study comparing NOACs and warfarin among this cohort of patients. This study was limited, however, by its retrospective nature, where no causal relationship could be determined between an oral anticoagulant and the desired outcomes. Furthermore, although bleeding rates were documented, no lab data or bloodwork, such as international normalized ratio, was recorded to compare bleeding risk.

Click to read the study in JAMA Network Open

Relevant Reading: Comparative risk of gastrointestinal bleeding with dabigatran, rivaroxaban, and warfarin: population based cohort study

In-Depth [retrospective cohort]: This subgroup analysis of the ARISTOPHANES study included 381 054 participants (81.6% of the ARISTOPHANES population) with nonvalvular AF and at least one risk factor for GI bleeding (prior medication [corticosteroids, antiplatelet, or NSAID], age >75 years, HAS-BLED score >3, prior GI bleed, stage III or greater chronic kidney disease). Participants were prescribed warfarin or a NOAC (apixaban, dabigatran, or rivaroxaban) between January 1, 2013, and September 30, 2015. The primary outcome was stroke/SE rates; the primary safety outcome was MB. The unadjusted incidence of stroke/SE was 2.3, 1.5, 1.7, and 1.6 per 100 person-years for those prescribed warfarin, apixaban, dabigatran, and rivaroxaban, respectively. The unadjusted incidence of MB was 7.0, 4.1, 4.3, and 6.4 per 100 person-years for those prescribed warfarin, apixaban, dabigatran, and rivaroxaban, respectively. Compared to warfarin, those prescribed apixaban (HR: 0.60 [95% CI: 0.52-0.68]), dabigatran (HR: 0.75 [95% CI: 0.64-0.88]), and rivaroxaban (HR: 0.79 [95% CI: 0.73-0.86]) had lower risk of stroke/SE. Compared to warfarin, those prescribed apixaban (HR: 0.59 [95% CI: 0.56-0.63]) and dabigatran (HR: 0.78 [95% CI: 0.70-0.86]) had a lower risk of MB; however, patients on rivaroxaban (HR: 1.11 [95% CI: 1.05-1.16]) had a higher risk of MB. When comparing NOACs, those prescribed apixaban had a lower risk of stroke/SE compared to rivaroxaban (HR: 0.74 [95% CI: 0.67-0.83]) and dabigatran (HR: 0.75 [95% CI: 0.62-0.91]). Additionally, apixaban demonstrated a lower risk of MB compared to rivaroxaban (HR: 0.55 [95% CI: 0.52-0.58]) and dabigatran (HR: 0.74 [95% CI: 0.62-0.88]).

RELATED REPORTS

#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation

Adding posterior wall isolation to pulmonary vein isolation not beneficial in ablation for patients with persistent atrial fibrillation — the CAPLA trial

The Apple Watch may have future applications in mental health disorders

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: anticoagulationatrial fibrillationbleeding eventsMajor Bleeding Eventswarfarin
Previous Post

Amoxicillin-clavulanate offers similar effectiveness for treating outpatient diverticulitis than metronidazole-with-fluoroquinolone

Next Post

Antiviral agents such as zanamivir and baloxavir are associated with improved time to symptom alleviation for seasonal influenza

RelatedReports

#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation
StudyGraphics

#VisualAbstract: Addition of posterior wall isolation to pulmonary vein isolation did not increase resolution of atrial fibrillation

January 17, 2023
Patient Basics: Atrial Fibrillation
Cardiology

Adding posterior wall isolation to pulmonary vein isolation not beneficial in ablation for patients with persistent atrial fibrillation — the CAPLA trial

January 16, 2023
Propofol appears safe and effective in procedural sedation for cardioversion
Chronic Disease

The Apple Watch may have future applications in mental health disorders

December 12, 2022
Women electing abortion more likely to be victims of domestic violence
Chronic Disease

Low-dose low-molecular weight heparin comparable to intermediate-dose for risk of venous thromboembolism in peripartum women

November 29, 2022
Next Post
Implementation of pneumococcal vaccine programs linked to decreased antibiotic prescription

Antiviral agents such as zanamivir and baloxavir are associated with improved time to symptom alleviation for seasonal influenza

Circulating tumor DNA used to monitor metastatic breast cancer

Pain and sleep may have a bidirectional causal relationship

ICU chlorhexidine baths do not reduce rates of hospital-acquired infections

Milrinone and dobutamine show no difference for cardiogenic shock treatment

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Chronic obstructive pulmonary disease associated with worse postoperative outcomes
  • Empagliflozin use is associated with slower progression of chronic kidney disease
  • Diagnostic tool may help identify cerebral palsy regardless of encephalopathy features
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options